Fluticasone reduces IL-6 and IL-8 production of cystic fibrosis bronchial epithelial cells via IKK-β kinase pathway

European Respiratory Journal

Volumn 21, Issue 4, 2003, Pages 574-581

  Escotte, S ^a   Tabary, O ^a   Dusser, D ^b   Majer Teboul, C ^c   Puchelle, E ^a   Jacquot, J ^a  

^a HÔPITAL MAISON BLANCHE   (France)

^b Hôpital Cochin ^*  (France)

^c GLAXOSMITHKLINE   (France)

Author keywords

Airway epithelium; Cystic fibrosis; Cytokines; Inhibitor of nuclear factor B kinase ; Nuclear factor B

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; DNA; FLUTICASONE; I KAPPA B ALPHA; I KAPPA B BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; PHOSPHOTRANSFERASE; RANTES;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRONCHUS MUCOSA; CELL STIMULATION; CONTROLLED STUDY; CYSTIC FIBROSIS; CYTOKINE PRODUCTION; CYTOSOL; DNA BINDING; DRUG MECHANISM; ENZYME ACTIVITY; EPITHELIUM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

EID: 0037385638     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.03.00031803     Document Type: Article

References (39)

1. Stutts MJ, Canessa CM, Olsen JC, et al. CFTR as a cAMP-dependent regulator of sodium channels. Science 1995; 269: 847-850.
2. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit care Med 1995; 15: 1075-1082.
3. Muhlebach MS, Stewart PW, Leigh MW, Noah TL. Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients. Am J Respir Crit Care Med 1999; 160: 186-191.
4. Blackwell TS, Stecenko AA, Christman JW. Dysregulated NF-kappaB activation in cystic fibrosis: evidence for a primary inflammatory disorder. Am J Physiol Lung Cell Mol Physiol 2001; 281: L69-L70.
5. Weber AJ, Soong G, Bryan R, Saba S, Prince A. Activation of NF-kappaB in airway epithelial cells is dependent on CFTR trafficking and Cl- channel function. Am J Physiol Lung Cell Mol Physiol 2001; 281: L71-L78.
6. Kammouni W, Figarella C, Marchand S, Merten M. Altered cytokine production by cystic fibrosis tracheal gland serous cells. Inject Immun 1997; 65: 5176-5183.
7. DiMango E, Ratner AJ, Bryan R, Tabibi S, Prince A. Activation of NF-kappaB by adherent Pseudomonas aeruginosa in normal and cystic fibrosis respiratory epithelial cells. J Clin Invest 1998; 101: 2598-2605.
8. Kube D, Sontich U, Fletcher D, Davis PB. Proinflammatory cytokine responses to P. aeruginosa infection in human airway epithelial cell lines. Am J Physiol Lung Cell Mol Physiol 2001; 280: L493-L502.
9. Heeckeren A, Walenga R, Konstan MW, Bonfield T, Davis PB, Ferkol T. Excessive inflammatory response of cystic fibrosis mice to bronchopulmonary infection with Pseudomonas aeruginosa. J Clin Invest 1997; 100: 2810-2815.
10. Chung KF, Adcock IM. Induction of nuclear factor-kappa B by exposure to ozone and inhibition by glucocorticoids. Methods Enzymol 2000; 319: 551-562.
11. Blackwell TS, Christman JW. The role of nuclear factor-kappa B in cytokine gene regulation. Am J Respir Cell Mol Biol 1997; 17: 3-9.
12. Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. J Clin Invest 2001; 107: 7-11.
13. Laitinen LA, Laitinen A, Haahtela T. A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. J Allergy Clin Immunol 1992; 90: 32-42.
14. Barnes PJ. Current issues for establishing inhaled corticosteroids as the antiinflammatory agents of choice in asthma. J Allergy Clin Immunol 1998; 101: S427-S433.
15. Bachert C, El-Akkad T. Patient preferences and sensory comparisons of three intranasal corticosteroids for the treatment of allergic rhinitis. Ann Allergy Asthma Immunol 2002; 89: 292-297.
16. Hart L, Lim S, Adcock I, Barnes PJ, Fan Chung K. Effects of inhaled corticosteroid therapy on expression and DNA-binding activity of nuclear factor kappaB in asthma. Am J Respir Crit care Med 2000; 161: 224-231.
17. Llewellyn-Jones CG, Harris TA, Stockley RA. Effect of fluticasone propionate on sputum of patients with chronic bronchitis and emphysema. Am J Respir Crit Care Med 1996; 153: 616-621.
18. Johnson M. Development of fluticasone propionate and comparison with other inhaled corticosteroids. J Allergy Clin Immunol 1998; 101: S434-S439.
19. Ek A, Palmberg L, Larsson K. Influence of fluticasone and salmeterol on airway effects of inhaled organic dust; an in vivo and ex vivo study. Clin Exp Immunol 2000; 121: 11-16.
20. Fokkens WJ, Godthelp T, Holm AF, Blom H, Klein-Jan A. Allergic rhinitis and inflammation: the effect of nasal corticosteroid therapy. Allergy, 1997; 52: 29-32.
21. Culpitt SV, Maziak W, Loukidis S, Nightingale JA, Matthews JL, Barnes PJ. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 1635-1639.
22. Tabary O, Escotte S, Couetil JP, et al. High susceptibility for cystic fibrosis human airway gland cells to produce IL-8 through the I kappa B kinase alpha pathway in response to extracellular NaCl content. J Immunol 2000; 164: 3377-3384.
23. Tabary O, Escotte S, Couetil JP, et al. Genistein inhibits constitutive and inducible NFkappaB activation and decreases IL-8 production by human cystic fibrosis bronchial gland cells. Am J Pathol 1999; 155: 473-481.
24. Tabary O, Zahm JM, Hinnrasky J, et al. Selective up-regulation of chemokine IL-8 expression in cystic fibrosis bronchial gland cells in vivo and in vitro. Am J Pathol 1998; 153: 921-930.
25. Escotte S, Danel C, Gaillard D, et al. Fluticasone propionate inhibits lipopolysaccharide-induced proinflammatory response in human cystic fibrosis airway grafts. J Pharmacol Exp Ther 2002; 302: 1151-1157.
26. Mizgerd JP, Scott ML, Spieker MR, Doerschuk CM. Functions of IkappaB proteins in inflammatory responses to Escherichia coli LPS in mouse lungs. Am J Respir Cell Mol Biol 2002; 27: 575-582.
27. Thomas LH, Friedland JS, Sharland M, Becker S. Respiratory syncytial virus-induced RANTES production from human bronchial epithelial cells is dependent on nuclear factor-kappa B nuclear binding and is inhibited by adenovirus-mediated expression of inhibitor of kappa B alpha. J Immunol 1998; 161: 1007-1016.
28. Ray P, Yang L, Zhang DH, Ghosh SK, Ray A. Selective up-regulation of cytokine-induced RANTES gene expression in lung epithelial cells by over expression of IkappaBR. J Biol Chem 1997; 272: 20191-20197.
29. Dhawan P, Richmond A. A novel NF-kappa B-inducing kinase-MAPK signaling pathway up-regulates NF-kappa B activity in melanoma cells. J Biol Chem 2002; 277: 7920-7928.
30. Bonfield TL, Konstan MW, Berger M. Altered respiratory epithelial cell cytokine production in cystic fibrosis. J Allergy Clin Immunol 1999; 104: 72-78.
31. Johnson M. Development of fluticasone propionate and comparison with other inhaled corticosteroids. J Allergy Clin Immunol 1998; 101: S434-S439.
32. Adcock IM, Nasuhara Y, Stevens DA, Barnes PJ. Ligand-induced differentiation of glucocorticoid receptor (GR) trans-repression and transactivation: preferential targeting of NF-kappaB and lack of I-kappaB involvement. Br J Pharmacol 1999; 127: 1003-1011.
33. Jaffuel D, Demoly P, Gougat C, et al. Transcriptional potencies of inhaled glucocorticoids. Am J Respir Crit Care Med 2000; 162: 57-63.
34. DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin M. A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature 1997; 388: 548-554.
35. Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev Immunol 2002; 2: 725-734.
36. Tojima Y, Fujimoto A, Delhase M, et al. NAK is an IkappaB kinase-activating kinase. Nature 2000; 404: 778-782.
37. Tsang KW, Ho PL, Lam WK, et al. Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis. Am J Respir Crit Care Med 1998; 158: 723-727.
38. Balfour-Lynn IM, Klein NJ, Dinwiddie R. Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis. Arch Dis Child 1997; 77: 124-130.
39. Esmailpour N, Hogger P, Rabe KF, Heitmann U, Nakashima M, Rohdewald P. Distribution of inhaled fluticasone propionate between human lung tissue and serum in vivo. Eur Respir J 1997; 10: 1496-1499.